Abstract
The field of toxicologic pathology is being impacted, as are other fields of science and medicine, by rapid transitions to take advantage of new science and technology. The new technology represents great opportunities to advance our understanding of toxicology and pathology to exciting new levels, but it also poses new challenges. We must be seriously engaged in that transition to assure that the outcome reflects the knowledge and discipline that are hallmarks of today's decision-making process in areas of product development and approval. New expertise will be required to deal with new issues. How well and how rapidly we adapt as the field moves from “... icities” to “ ... omics” will, at least in part, determine the role of toxicologic pathologists in the product development and approval processes of the future.